On average, people with Down syndrome have widespread immune system dysregulation, which can impact many aspects of health. We have embarked on a multitude of studies to better understand this immune dysregulation and learn how to normalize immune function.
In this study, we focus on a drug called tofacitinib to treat immune-driven skin conditions that are more common in people with Down syndrome, including alopecia aerata, atopic dermatitis, hidradenitis suppurativa, psoriasis, and vitiligo.
We will assess three main outcomes in adults with Down syndrome:
In addition, in a more exploratory manner, we will begin to ask if normalizing immune function with tofacitinib can improve other autoimmune conditions that people with Down syndrome are pre-disposed to and improve cognition or overall quality of life.
You can also call us at 303-724-0491.